2 patents currently held
59 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Jul 2027. from the record
Of the 59 now held by other companies, 25 were conveyed to Ucb Biopharma SRL in the filing they arrived in, and 34 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2027
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jul 2027 · High confidence
Also notable
Ends Jan 2037 · High confidence
Device for Continuously Filtering Material Mixtures
US 7,824,544
Renewed at every maintenance window since the 2010 grant; no more fees are due before its term ends in 2027.
Iminotetrahydropyrimidinone Derivatives as Plasmepsin V Inhibitors
US 11,136,310
Granted 2021. Computed term ends 2037.
Formerly held, still cited
Notable
Ends Jun 2032 · High confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2032.
conveyed to Ucb Pharma S.A. - now held by Ucb Developed Brands SRL
Also notable
Ends Nov 2038 · High confidence
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
conveyed to Ucb Biopharma SPRL - now held by Ucb Biopharma SRL
Also notable
Ends Jun 2031 · High confidence
Cited by 22 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
conveyed to Ucb Pharma, S.A.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 4 terms have ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Iminotetrahydropyrimidinone Derivatives as Plasmepsin V Inhibitors | 1 in force | to Jan 2037 |
| Device for Continuously Filtering Material Mixtures | 1 in force | to Jul 2027 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,824,544 | Device for Continuously Filtering Material Mixtures In force · High confidence | In force | High confidence | |
| US 11,136,310 | Iminotetrahydropyrimidinone Derivatives as Plasmepsin V Inhibitors held by Ucb Biopharma SRL In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 59 patents in force now held by others · 113 patents ended · 23 applications pending · 66 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term